oxandrolone (oxandrin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Oxandrolone is a synthetic, orally active anabolic-androgenic steroid. Oxandrolones interact with androgen receptors in target tissues. Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Side effects include: elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations). Cardiovascular side effects have included edema, with and without congestive heart failure. Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.   NCATS

Chemistry

  • SMILES: C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C
  • InChIKey: QSLJIVKCVHQPLV-PEMPUTJUSA-N
  • Mol. Mass: 306.4397
  • ALogP: 3.54
  • ChEMBL Molecule:
    oxandrolone  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1.0278 - $2.8728
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

anavar | lonavar | ossandrolone | oxandren | oxandrin | oxandrolon | oxandrolona | oxandrolone | oxandrolonum | protivar | sc-11585 | vasorome

Organizations (27)

Research & Development (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (4)


 

HIV Wasting Syndrome

Osteoporosis (approved 1964)

Turner Syndrome

Weight Loss (approved 1964)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Anemia (Phase 2)

Biological Availability (Phase 1)

Body Weight (Phase 3)

Burns (Phase 2/Phase 3)

Drugs, Generic (Phase 1)

Dwarfism (Phase 2)

Fanconi Anemia (Phase 1)

Heart Defects, Congenital (Phase 1/Phase 2)

Heart Diseases (Phase 1/Phase 2)

HIV Wasting Syndrome (Phase 4)

Iron Deficiencies (Phase 2)

Klinefelter Syndrome (Phase 2)

Malnutrition (Phase 1)

Neoplasms (Phase 3)

Pressure Ulcer (Phase 3)

Rotator Cuff Injuries (Phase 2)

Turner Syndrome (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 18
  • # of Trial Organizations: 23

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue